NWBOOTCPharmaceutical PreparationsFiscal year ends December 31
NORTHWEST BIOTHERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.16−0.00 (-0.88%)
Close on Oct 19, 2026
- Market cap
- $254.79M
- P/E (TTM)
- –
- Dividend yield
- –
Northwest Biotherapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Northwest Biotherapeutics | Industry median |
|---|---|---|
| Market Cap | $264.60M | $166.30M |
| Enterprise Value | $276.24M | $88.19M |
| PS Ratio | 121.77 | 3.65 |
Enterprise value
| Measure | Northwest Biotherapeutics | Industry median |
|---|---|---|
| EV / Sales | 127.12 | 2.51 |
Income (trailing twelve months)
| Measure | Northwest Biotherapeutics | Industry median |
|---|---|---|
| Revenue | $2.17M | $58.34M |
| Operating Income | -$50.33M | -$21.40M |
| Net Income | -$37.73M | -$22.46M |
| EBITDA | -$47.61M | -$16.91M |
Margins
| Measure | Northwest Biotherapeutics | Industry median |
|---|---|---|
| Operating Margin | -2316.1% | -44.0% |
| Profit Margin | -1736.4% | -40.2% |
| EBITDA Margin | -2190.8% | -30.2% |
| FCF Margin | -2290.3% | -9.27% |
Returns
| Measure | Northwest Biotherapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -71.5% | -40.9% |
| Return on Capital Employed (ROCE) | -1944.0% | -38.1% |
Growth
| Measure | Northwest Biotherapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 98.6% | 5.96% |
| Revenue Growth (3Y CAGR) | -6.45% | 2.25% |
| Revenue Growth (5Y CAGR) | 1.31% | 6.48% |
Balance sheet
| Measure | Northwest Biotherapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $595.00K | $61.43M |
| Total Debt | $12.24M | $118.52M |
| Net Cash (Debt) | -$11.64M | $15.35M |
| Net Cash Per Share | -$0.01 | $0.66 |
| Equity (Book Value) | -$45.17M | $49.09M |
| Book Value Per Share | -$0.03 | $1.37 |
| Tangible Book Value | -$97.73M | $23.52M |
| Working Capital | -$70.78M | $76.81M |
Financial position
| Measure | Northwest Biotherapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.04 | 3.34 |
| Quick Ratio | 0.01 | 2.44 |
| Interest Coverage | -5.34 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Northwest Biotherapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$48.34M | -$12.35M |
| Capital Expenditures | -$1.43M | -$1.08M |
| Free Cash Flow | -$49.77M | -$20.22M |
| FCF Per Share | -$0.03 | -$0.42 |
Efficiency
| Measure | Northwest Biotherapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.04 | 0.39 |
| Revenue Per Employee | $20.70K | $404.87K |
| Profits Per Employee | -$359.34K | -$703.34K |
| Employee Count | 105 | 74 |
Dividends and yields
| Measure | Northwest Biotherapeutics | Industry median |
|---|---|---|
| Earnings Yield | -14.3% | -23.3% |
| FCF Yield | -18.8% | -8.72% |
| Buyback Yield | -3.73% | -0.59% |
| Shareholder Yield | -3.73% | 0.00% |
Shares
| Measure | Northwest Biotherapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 1,705,640,000 | 58,127,000 |
| Shares Change (QoQ) | 3.88% | 0.54% |
| Float | 1,705,640,000 | 49,136,700 |
| Shares Held by Insiders | 0.00% | 11.6% |
| Shares Held by Institutions | 0.13% | 59.4% |
Scores
| Measure | Northwest Biotherapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -29.79 | -0.22 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Northwest Biotherapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.